Jacob Gottlieb Launches New Healthcare Investment Firm Altium Capital

Healthcare investment tycoon, Jacob Gottlieb, MD, CFA, PRIMA has cofounded a new pharmaceutical and healthcare investment firm, Altium Capital. This new investment venture is based out of NYC and seeks to invest in opportunities in the healthcare industry. The opportunities they seek to invest in are growing companies that are working to create new medical treatments and advances. Mainly, those for diseases such as cancer, diabetes, and Alzheimer’s.

Altium Capital has recently invested in companies Oramed Pharmaceuticals (ORMP), Amarin Corporation (AMRN) and Oragenics. Oramed Pharmaceuticals is one of their first major investments, has invented an alternative oral treatment for patients with diabetes. Rather than using an insulin pump, they have engineered and released an alternative oral method, an ingestible insulin capsule (ORMD-0801) as well as an oral Glucagon-like peptide-1 (GLP-1) analog (exenatide) capsule (ORMD-0901).

Amarin is a Dublin based company with an office in Bedminster, New Jersey who are working to develop drugs that improve cardiovascular health. Oragenics was founded by two physicians in 1996, to create healthcare solutions based on the concept of replacement therapy. This therapy is based on the concept of replacing harmful bacteria with good bacteria to cure health issues. Oragenics are also working on an effective treatment for oral mucositis and to fight other infectious diseases.

Prior to founding Altium Capital, Gottlieb was the founder of Visium Asset Management. Prior to that he was a founding member of Balyasny Asset Management, L.P.

Gottlieb‘s educational background provides him with excellent knowledge of both the healthcare and investment industries. His educational background includes a BA in Economics from Brown University, where he graduated magna cum laude and an MD from New York University Medical School. In 2001, he obtained his Chartered Financial Analyst (CFA) charter from the Association for Investment Management and Research (AIMR) and in 2010, he earned his P.R.M. designation from the Professional Risk Managers’ International Association.

Leave a Reply

Your email address will not be published. Required fields are marked *